Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 7/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.49 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL16799767 | 1.00 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| Bromide SCHEMBL17822691 | 1.00 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| Bromide SCHEMBL19876392 | 1.00 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| Bromide SCHEMBL18106675 | 1.00 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| Bromide SCHEMBL18129441 | 1.00 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| Bromide SCHEMBL17822680 | 1.00 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| SCHEMBL2198525 | 0.98 | KDM1A (0.58) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| SCHEMBL2197651 | 0.98 | KDM1A (0.58) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| SCHEMBL2798417 | 0.98 | KDM1A (0.58) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| SCHEMBL491107 | 0.98 | KDM1A (0.58) | KDM1AMAOAGRIN2BFUCA1SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464891-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3230264-B1 | 3-OXO-3-(ARYLAMINO)PROPANOATES, A PROCESS FOR THEIR PREPARATION, AND THEIR USE IN PREPARING PYRROLIDINONES | FMC CORP (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10227286-B2 | 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones | FMC CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| EP-3075726-B1 | UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FORMYL PEPTIDE RECEPTOR LIKE 1 (FPRL-1) AGONISTS | KYORIN SEIYAKU KK (JP) | 2017-11-08 | — | — | EP | disclosed |
| EP-3230264-A1 | 3-OXO-3-(ARYLAMINO)PROPANOATES, A PROCESS FOR THEIR PREPARATION, AND THEIR USE IN PREPARING PYRROLIDINONES | E. I. du Pont de Nemours and Company (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3075726-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2016-10-05 | — | — | EP | disclosed |
| WO-2016094117-A1 | 3-OXO-3-(ARYLAMINO)PROPANOATES, A PROCESS FOR THEIR PREPARATION, AND THEIR USE IN PREPARING PYRROLIDINONES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227286-B2 | 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones | SDHA, SDHB, NDUFV3 | ACHE 1886/4885KDM1A 898/4885MAOA 246/4885 |
| US-10464891-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | ACHE 4545/4885KDM1A 4486/4885MAOA 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.